No Data
No Data
Sinopharm Medical-B (06669) released its interim performance, with a net income of 39.957 million yuan, a year-on-year increase of 78.6%.
Xian Ruida Medical-B(06669) released its six-month performance for the period ending June 30, 2024, with earnings of 2.92...
先瑞達醫療-B:截至2024年6月30日止六個月之中期業績公告
Xianruida Medical-B (06669.HK) plans to hold a board of directors meeting on August 30th to approve the mid-term performance.
Xianruida Medical - B (06669.HK) announced on August 20 that the company will hold a board of directors meeting on Friday, August 30, 2024 to consider and approve the unaudited mid-year performance of the company and its subsidiaries until June 30, 2024, as well as to consider the distribution of mid-year dividends (if any).
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Sinocare Medical-B (06669.HK): Silvio Rudolf SCHAFFNER was appointed as a non-executive director.
On June 12th, Geelong News reported that Mr. Silvio Rudolf Schaffner, the Executive Director and Chief Operating Officer of Aier Ophthalmology Inc. (06669.HK), has been repositioned as a non-executive director due to wanting to devote more time to his personal affairs, effective June 12, 2024.
No Data